Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Teva's Huntington Disease Drug Receives CRL From The FDA

Published 05/31/2016, 09:57 PM
Updated 07/09/2023, 06:31 AM
TEVA
-
BMY
-
ANIP
-
TVTX
-

Teva Pharmaceutical Industries Limited (NYSE:TEVA) suffered a regulatory setback with the FDA issuing a complete response letter (CRL) for the new drug application for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD).

In its CRL, the FDA has asked Teva to re-analyze blood levels of certain metabolites. Teva noted that these metabolites are not novel and are also observed in patients taking tetrabenazine or deutetrabenazine. Importantly, the regulatory agency did not ask the company to conduct additional studies.

Teva plans to work closely with the FDA to address the issue. A response to the CRL will be submitted in the third quarter of 2016.

Although the CRL on SD-809 comes as a disappointment for Teva, the most important thing is that the FDA has not asked the company for additional studies to be conducted, which would have delayed the candidate from entering the U.S. markets further.

Per the company’s press release, HD is a rare and fatal neurodegenerative disorder affecting approximately one in 7,000–10,000 people in western countries. While chorea is one of the most prominent physical manifestations of this disease, it occurs in roughly 90% of patients at some point in the course of their illness.

Notably, SD-809 is the first deuterated product to be reviewed by the FDA. Considering the lack of treatments for HD, its approval will be a huge boost for the patient population as well as for the company.

We note that SD-809 became a part of Teva’s pipeline following the May 2015 acquisition of Auspex Pharmaceuticals.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Apart from HD, Teva is also evaluating SD-809 for a couple of additional indications including treatment of patients with tardive dyskinesia (TD) and Tourette syndrome (TS). Currently, a phase III (AIM-TD) efficacy and safety study in patients with moderate-to-severe TD is in progress with additional data from the study anticipated later in 2016. The company is also planning to evaluate SD-809 for the treatment of tics associated with TS.

Teva is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) , Retrophin, Inc. (NASDAQ:RTRX) and Bristol-Myers Squibb Company (NYSE:BMY) . All three stocks sport a Zacks Rank #1 (Strong Buy).



BRISTOL-MYERS (BMY): Free Stock Analysis Report

RETROPHIN INC (RTRX): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.